The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats.

BACKGROUND In previous studies, pyridoxamine (PM) limited the formation of advanced glycation end products (AGEs) and development of nephropathy in streptozotocin-diabetic rats without affecting glycemic control. However, the lipid-lowering effects of PM and the correlation of plasma cholesterol and triglycerides with AGEs in skin collagen suggested that lipids might be an important source of AGEs in the diabetic rat. This study addresses the effects of hyperlipidemia on formation of advanced glycation and lipoxidation end products (AGE/ALEs) and the effects of PM on hyperlipidemia, hypertension, AGE/ALE formation, and development of nephropathy in the nondiabetic, Zucker obese rat. METHODS Three groups of Zucker rats were studied: lean (Fa/fa), untreated fatty (fa/fa), and fa/fa treated with PM (2 g/L drinking water). Blood pressure, plasma lipids and creatinine, and urinary albumin were measured monthly. AGE/ALEs were measured in skin collagen by high-performance liquid chromatography (HPLC) and gas chromatography/mass spectrometry (GC/MS). Changes in wall thickness of the aorta and renal arterioles were evaluated by light microscopy. RESULTS AGE/ALEs formation was increased two- to threefold in skin collagen of obese versus lean rats. PM inhibited the increases in AGE/ALEs in collagen, and significantly decreased the rise in plasma triglycerides, cholesterol, and creatinine, corrected hypertension and thickening of the vascular wall, and nearly normalized urinary protein and albumin excretion in Zucker fa/fa rats. CONCLUSION Lipids are an important source of chemical modification of tissue proteins, even in the absence of hyperglycemia. PM inhibited AGE/ALE formation and hyperlipidemia and protected against renal and vascular pathology in a nondiabetic model.

[1]  D. A. Maddox,et al.  Prevention of obesity-linked renal disease: age-dependent effects of dietary food restriction. , 2002, Kidney international.

[2]  M. Steffes,et al.  Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. , 2002, Kidney international.

[3]  T. Metz,et al.  A Post-Amadori Inhibitor Pyridoxamine Also Inhibits Chemical Modification of Proteins by Scavenging Carbonyl Intermediates of Carbohydrate and Lipid Degradation* , 2002, The Journal of Biological Chemistry.

[4]  D. L. Price,et al.  Chelating Activity of Advanced Glycation End-product Inhibitors* , 2001, The Journal of Biological Chemistry.

[5]  S. Takebayashi,et al.  Obesity Associated with Hypertension or Hyperlipidemia Accelerates Renal Damage , 2001, Pathobiology.

[6]  A. Schmidt,et al.  The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. , 2001, The Journal of clinical investigation.

[7]  A. Cerami,et al.  Protein glycation, diabetes, and aging. , 2001, Recent progress in hormone research.

[8]  R. Peterson.  THE ZUCKER DIABETIC FATTY (ZDF) RAT , 2000 .

[9]  A. Jenkins,et al.  Pyridoxamine, an Inhibitor of Advanced Glycation Reactions, Also Inhibits Advanced Lipoxidation Reactions , 2000, The Journal of Biological Chemistry.

[10]  J. Baynes,et al.  Glycoxidation and lipoxidation in atherogenesis. , 2000, Free radical biology & medicine.

[11]  F. Sestier,et al.  Metabolic syndrome X: a review. , 2000, The Canadian journal of cardiology.

[12]  W. Keane,et al.  The role of lipids in renal disease: future challenges. , 2000, Kidney international. Supplement.

[13]  B. Hansen.  The Metabolic Syndrome X , 1999, Annals of the New York Academy of Sciences.

[14]  M. Portero-Otín,et al.  Thyroid status modulates glycoxidative and lipoxidative modification of tissue proteins. , 1999, Free radical biology & medicine.

[15]  M. White,et al.  Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. , 1999, The Journal of clinical investigation.

[16]  T. Osawa,et al.  Formation of Nepsilon-(hexanonyl)lysine in protein exposed to lipid hydroperoxide. A plausible marker for lipid hydroperoxide-derived protein modification. , 1999, The Journal of biological chemistry.

[17]  O. Samuelsson,et al.  Lipoprotein abnormalities as a risk factor for progressive nondiabetic renal disease. , 1999, Kidney international. Supplement.

[18]  G. Kaysen,et al.  Hyperlipidemia and renal disease: the use of animal models in understanding pathophysiology and approaches to treatment. , 1999, Wiener klinische Wochenschrift.

[19]  R. Khalifah,et al.  Amadorins: novel post-Amadori inhibitors of advanced glycation reactions. , 1999, Biochemical and biophysical research communications.

[20]  C van Ypersele de Strihou,et al.  Alterations in nonenzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremic complications. , 1999, Kidney international.

[21]  J. Baynes,et al.  Role of the Maillard Reaction in Aging of Tissue Proteins , 1998, The Journal of Biological Chemistry.

[22]  C. Stehouwer,et al.  Can reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with non‐insulin‐dependent diabetes mellitus? , 1997, European journal of clinical investigation.

[23]  D. Heudes,et al.  Reduction of insulin and triglycerides delays glomerulosclerosis in obese Zucker rats. , 1997, Kidney international.

[24]  G. Guidotti,et al.  Phosphate Transport in Yeast Vacuoles* , 1997, The Journal of Biological Chemistry.

[25]  T. Saito.  Abnormal lipid metabolism and renal disorders. , 1997, Tohoku journal of experimental medicine.

[26]  A. Booth,et al.  In Vitro Kinetic Studies of Formation of Antigenic Advanced Glycation End Products (AGEs) , 1997, The Journal of Biological Chemistry.

[27]  A. Jenkins,et al.  Quantification of malondialdehyde and 4-hydroxynonenal adducts to lysine residues in native and oxidized human low-density lipoprotein. , 1997, The Biochemical journal.

[28]  D. Heudes,et al.  Early influx of glomerular macrophages precedes glomerulosclerosis in the obese Zucker rat model. , 1996, Journal of the American Society of Nephrology : JASN.

[29]  David H. Williams,et al.  Phosphorylation of SLP-76 by the ZAP-70 Protein-tyrosine Kinase Is Required for T-cell Receptor Function* , 1996, The Journal of Biological Chemistry.

[30]  J. Baynes,et al.  Role of the Maillard Reaction in Diabetes Mellitus and Diseases of Aging , 1996, Drugs & aging.

[31]  T. Lyons,et al.  The Advanced Glycation End Product, N-(Carboxymethyl)lysine, Is a Product of both Lipid Peroxidation and Glycoxidation Reactions (*) , 1996, The Journal of Biological Chemistry.

[32]  A. Booth,et al.  Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: comparison with aminoguanidine. , 1996, Biochemical and biophysical research communications.

[33]  A. J. Pijl,et al.  Hypertensive diabetic rats in pharmacological studies. , 1996, Pharmacological research.

[34]  B. Kasiske,et al.  Lovastatin retards the progression of established glomerular disease in obese Zucker rats. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[35]  W. Keane,et al.  Lipid abnormalities and changes in plasma proteins in glomerular diseases and chronic renal failure , 1993, Current opinion in nephrology and hypertension.

[36]  L. Sayre,et al.  Pyrrole formation from 4-hydroxynonenal and primary amines. , 1993, Chemical research in toxicology.

[37]  T. Lyons,et al.  Accumulation of Maillard reaction products in skin collagen in diabetes and aging. , 1993, The Journal of clinical investigation.

[38]  B. Kasiske,et al.  The Zucker rat model of obesity, insulin resistance, hyperlipidemia, and renal injury. , 1992, Hypertension.

[39]  T. Kurtz,et al.  The Zucker Fatty Rat as a Genetic Model of Obesity and Hypertension , 1989, Hypertension.

[40]  D. Sampson,et al.  Analysis of B-6 vitamers and pyridoxic acid in plasma, tissues and urine using high performance liquid chromatography , 1989 .

[41]  B. Kasiske,et al.  Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. , 1988, Kidney international.

[42]  M. Kowala,et al.  Cellular changes during hypertension: a quantitative study of the rat aorta. , 1986, Experimental and molecular pathology.

[43]  E. Schleicher,et al.  Kinetic analysis of glycation as a tool for assessing the half-life of proteins. , 1986, Biochimica et biophysica acta.

[44]  B. Kasiske,et al.  Effects of genetic obesity on renal structure and function in the Zucker rat. , 1985, The Journal of laboratory and clinical medicine.

[45]  P. Anversa,et al.  Morphometric analysis of hypertension-induced hypertrophy of rat thoracic aorta. , 1977, The American journal of pathology.

[46]  H. Stegemann,et al.  Determination of hydroxyproline. , 1967, Clinica chimica acta; international journal of clinical chemistry.

[47]  Bauer Wc,et al.  A quantitative study of glomerular enlargement in children with tetralogy of Fallot. A condition of glomerular enlargement without an increase in renal mass. , 1960 .